MedTrace Logo

Effects of Immediate and Delayed Repeated Cold Exposure After Physical Exertion

NCT06813690 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-03-04

No results posted yet for this study

Summary

The goal of this clinical trial is to learn if applying cold therapy can reduce swelling, inflammation, and pain after physical activity in adults who experience muscle soreness (Delayed Onset Muscle Soreness, or DOMS). The main questions it aims to answer are:

* Can cold therapy reduce swelling and inflammation in muscles after exercise?
* Does cold therapy reduce muscle pain and discomfort (DOMS)?

Researchers will compare participants using the Axanova Cold Hot Pearls Maxi Pack to those not receiving any cold therapy to see if the cold application improves recovery outcomes.

Participants will:

* Perform physical activity designed to induce muscle soreness.
* Use the Axanova Cold Hot Pearls Maxi Pack on the affected area as directed.
* Report their level of muscle pain, stiffness, and swelling over the following 72 hours.

The study aims to provide new insights into the effectiveness of cold therapy for muscle recovery, focusing on pain relief, reduced swelling, and improved recovery time.

Conditions

  • Delayed Onset Muscle Soreness (DOMS)
  • Inflammation
  • Muscle Pain
  • Muscle Damage

Interventions

DEVICE

Cold Therapy with Axanova Cold Hot Pearls Maxi Pack

This intervention involves the application of the Axanova Cold Hot Pearls Maxi Pack, a cooling device designed to provide targeted cold therapy. The device will be used to cool both thighs for 20-minute sessions, three times per day, following a muscle soreness protocol. The cold therapy aims to reduce inflammation, swelling, and muscle pain associated with Delayed Onset Muscle Soreness (DOMS). The intervention begins immediately after completing the muscle soreness protocol in Group A, and 24 hours later in Group B. Participants will receive cooling treatment for a total of 72 hours, with temperature and duration carefully monitored to ensure effective cooling.

Sponsors & Collaborators

  • University of Applied Sciences and Arts of Southern Switzerland

    lead OTHER

Principal Investigators

  • Ron Clijsen, Prof. Dr. · University of Applied Sciences of Southern Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-03-17
Primary Completion
2025-10-16
Completion
2025-10-16

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06813690 on ClinicalTrials.gov